EPO and myelodysplastic syndrome: The translational application in our center of low dose of DFX for 6 low risk MDS patients showed improvement of erythropoiesis and a longer median time to transfusion dependence: 9.6 versus 6.1 months, if we consider the results obtained in the European cohort concerning MDS EPO refractory patients [46].